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Abstract
Miscarriage is the most common complication of pregnancy. Pre-clinical miscarriage has an estimated incidence of 30%,
whilst clinical miscarriage has an incidence of 12-15%. Two thirds of pregnancies lost to miscarriage are believed to be
attributable to defective placentation, thus a number of studies have sought to identify markers of defective placentation
that could be used as clinical biomarkers of miscarriage. Decreased soluble FMS-like tyrosine kinase-1 (sFlt1), placental
growth factor (PlGF), and soluble endoglin (sEng) in the maternal circulation during the first trimester have recently been
proposed as potential markers of pregnancy loss. However, in these studies clinical samples were only obtained once
women had presented with symptoms of miscarriage. In this study we prospectively screened serum samples collected
from asymptomatic women with a viable fetus. We assessed maternal serum levels of sFlt1, PlGF and sEng across the first
trimester of normal pregnancy and compared levels between women who continued to a live birth, to those who
subsequently miscarried. Both sFlt1 and PlGF significantly (p#0.05) increased across gestation in normal pregnancy with
serum levels rising from 0.6560.12 ng/ml at 6 weeks to 1.8560.24 ng/ml at 12 weeks for sFlt1, and 57.2619.2 pg/ml to
106622.7 pg/ml for PlGF. sEng remained unchanged throughout the the first trimester. Importantly we detected a
significant (35%, p#0.05) decrease in sFlt1 levels between our control and miscarriage cohort, however there was significant
overlap between cases and controls, suggesting serum sFlt1 is unlikely to be useful as a clinical biomarker in asymptomatic
women. Nevertheless, our data suggests a dysregulation of angiogenic factors may be involved in the pathophysiology of
miscarriage.
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Introduction
It is well established that early embryo development in the
human occurs in a hypoxic environment, and that an increase in
placental oxygen levels is observed at the end of the first trimester
once maternal blood flow in to the intervillous space is established
[1]. Thus throughout the first trimester of normal pregnancies,
there is a delicately balanced and tightly controlled state that
ensures the developing placenta establishes correctly to allow
adequate support and nutrition for the fetus throughout the
pregnancy [2].
In the last decade it has been hypothesized that during early
development the placenta limits oxygen supply to the developing
fetus as a mechanism to protect it against the damaging effects of
oxygen free radicals [3]. This protective mechanism is essential to
normal development as during this time placental and embryonic
cells undergo significant cell division exposing their DNA to
potentially deleterious effects of oxidative stress [4].
Pre-clinical pregnancy loss in which conception occurs but ends
before delayed menses has an estimated incidence of about 30%
[5], whilst clinical pregnancy loss, or clinical miscarriage has an
estimated incidence of 12–15% [6,7]. This means that miscarriage
is the most common complication of pregnancy. Two-thirds of
pregnancies lost to miscarriage are believed to be attributable to
defective placentation associated with an absence of physiological
change in maternal spiral arteries and a premature onset of
maternal circulation throughout the placenta [2]. This not only
causes mechanical damage to the villous tissue but also results in
widespread and indirect oxygen mediated trophoblastic damage
[2,8] and eventual expulsion of the conceptus and placenta.
Decreased placental growth factor (PlGF), soluble FMS-like
tyrosine kinase -1 (sFlt1) and soluble endoglin (sEng) in the maternal
circulation during the first trimester have recently been proposed as
potentialmarkersofearlypregnancyloss[9,10,11,12].Thereissome
biological plausibility given sFlt1 and possibly sEng are upregulated
by placental hypoxia. sFlt1 is upregulated by cytotrophoblasts under
reduced oxygen whilst PlGF is the most abundantly regulated
angiogenic factor in uncomplicated first trimester decidua [9].
Interestingly, it was recently reported both sFlt1 and PlGF are
significantly decreased in the maternal serum of miscarriage
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32509patients compared to asymptomatic controls [11,12]. Further-
more, in a cohort with threatened miscarriage (vaginal bleeding
during pregnancy), those with depressed sFlt1, PlGF and sEng
were all significantly more likely to undergo complete miscarriage
[11]. However, in all of these studies clinical samples were only
obtained once women had presented with symptoms of miscar-
riage (abdominal pain and bleeding). Therefore, the pathophys-
iological process of miscarriage in these studies is likely to be
already advanced. Potentially, a more useful biomarker would be
one that predicts miscarriage among women who are still
asymptomatic with a viable fetus. It may be that such a biomarker
could flag cases at a higher risk of miscarriage but are at an early
stage of the process where potential therapeutic interventions
could be successfully administered.
In 2004, we initiated the Mercy Early Pregnancy Study (MEP),
a prospective collection of serum samples from asymptomatic
women in the first trimester. The primary aim of this study was to
identify predictive biomarkers of miscarriage and to validate those
previously proposed.
In this study, we used samples selected from the MEP study to
examine whether the angiogenic factors sFlt1, PlGF and sEng
serum levels are altered in asymptomatic women with viable
pregnancies who are destined to miscarry.
Materials and Methods
Ethics statement
This study was approved by the Mercy Hospital for Women
Ethics committee. All women gave informed written consent to
participate in the study.
Sample collection
Blood samples were collected during The Mercy Early Pre-
gnancy Study, a prospective study designed to identify predictive
serum biomarkers of miscarriage among asymptomatic women
attending their first prenatal clinic visit between 6 and 12 weeks of
gestation [13]. On the day of blood sampling, fetal cardiac activity
was confirmed by ultrasound and women had no signs or
symptoms of early pregnancy loss. Miscarriage was defined as
spontaneous loss of pregnancy at less than 20 weeks gestation.
Study groups
From the 1044 samples collected during the Mercy Early
Pregnancy Study, we selected a case control cohort of 181 samples
consisting of 159 controls (women who went on to deliver a live
baby at term) and 22 miscarriage samples. Baseline characteristics
of all women were recorded including maternal age, gravidity, and
parity (Table 1). Gestational age for the miscarriage cohort was
calculated from menstrual dates and either menstrual dates or by
first trimester ultrasound for controls. Approximately 8 mL of
venous blood was collected into vacuette serum clot separator
tubes (Greiner Bio-One, Kremsmu ¨nster, Austria) without addi-
tives. The tubes were centrifuged at 3000 g for 10 minutes, and
the serum was collected and stored at 280uC until analysis. All
samples were promptly processed and frozen within hours of
sample collection.
Samples were divided in to gestational age at the time of blood
collection. For control samples, n=22 at 6 weeks, n=29 at 7
weeks, n=33 at 8 weeks, n=22 at 9 weeks, n=26 at 10 weeks,
n=21 at 11 weeks, n=6 at 12 weeks. The gestational age of
miscarriage samples were 6–10 weeks with n=5 at 6 weeks, n=8
at 7 weeks, n=6 at 8 weeks, n=2 at 9 weeks and n=1 at 10
weeks.
Immunoassays
Samples were assayed for Soluble Flt-1 (sFlt1), Placental growth
factor (PlGF) and soluble endoglin (sEng) using commercially
available duoset ELISAs from R&D systems (MN, USA). Proteins
were measured in serum samples according to manufacturer’s
instructions. The minimum detection limit for the respective assays
were sFlt1: 39 pg/ml, PlGF: 15.6 pg/ml, sEng: 125 pg/ml.
Statistical Analysis
For baseline patient characteristics, Mann-Whitney or chi-
squared test was used to compare between control and miscarriage
groups.
Table 1. Characteristics of study participants.
Controls (n=159) Miscarriage (n=22)
Maternal age (years) 30.0 (21–44) 34.5 (20–43)
Gravidity[%(n)]
1 33 (52) 27 (6)
2 26 (42) 27 (6)
$3 41 (65) 45 (10)
Parity [%(n)]
0 53 (85) 59 (13)
1 32 (51) 23 (5)
$2 14 (23) 18 (4)
Gestation at sampling (wks+days) 8+4( 6 +0212+6) 7+5( 6 +2210+1)**
Gestation at 1
st symptoms (wks+days) n/a 11+0( 7 +0212+3)
Gestation when the miscarriage was confirmed by
ultrasound (wks+days)
n/a 11+0( 7 +0217+0)
Gestation at delivery (wks+days) 39+3( 3 2 +0242+0) n/a
Birth weight (g) 3493 (1785–4680) n/a
Data provided as the median, with range given in brackets. p#0.01=**.
doi:10.1371/journal.pone.0032509.t001
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gestation, one-way ANOVAs were performed, with Dunn’s post-
hoc test indicating differences between gestations. To assess
differences between control and miscarriage groups, data was
initially corrected for changes across gestation by conversion to
MoMs. Mann-Whitney test was then used. P values were
considered significant at p,0.05.
Results
Patient characteristics
The median maternal age forcontrolwomen was30 years,with a
range of 21–44. This was not significantly different to the
miscarriage cohort (median of 34.5 years, range 20–43, p=0.46).
There was also no significant difference between gravidity and
paritybetweengroupswith 33%,27%and 41%ofcontrolshaving a
gravidity of 1, 2 or 3 respectively compared to 27%, 27% and 45%
for the miscarriage cohort (p=0.87, chi-squared test). For parity in
the control group 53% were nulliparous, 32% were primiparous,
and14%had2ormorelive birthscomparedto59%,23%and18%
for the miscarriage cohort. The median gestation at sampling for
miscarriage patients was significantly lower than control. Miscar-
riage samples did not include any 11 or 12 week samples, and thus
for multiples of the median comparisons (MoM) only 6–10 week
control samples were included.
For the miscarriage cohort, 12/22 patients attended the hospital
with symptoms of miscarriage, whilst 10/22 were asymptomatic
prior to diagnosis. n=18 of the miscarriage patients were
diagnosed in the first trimester, n=4 in the 2
nd trimester. The
median gestation when the samples were taken was over three
weeks from the date when the women suffered their 1
st symptoms
of miscarriage and/or were diagnosed with a miscarriage (table 1).
sFlt1 and PlGF increase across early pregnancy in control
samples
sFlt1 serum concentrations rose significantly (p#0.05) across
gestation during early pregnancy with mean serum concentrations
(6 SEM) being 0.6560.12 ng/ml at 6 weeks, 0.8960.1 ng/ml at
7 weeks, 1.1260.11 ng/ml at 8 weeks, 1.3160.12 ng/ml at 9
weeks, 1.1760.1 ng/ml at 10 weeks, 1.9460.15 ng/ml at 11
weeks and 1.8560.24 ng/ml at 12 weeks (Figure 1A).
PlGF serum concentrations significantly rose (p#0.05) across
gestation during early pregnancy with mean serum concentrations
(6 SEM) being 57.2619.2 pg/ml at 6 weeks, 50.465.8 pg/ml at
7 weeks, 57.5612 pg/ml at 8 weeks, 68.3613.5 pg/ml at 9 weeks,
60.769.6 pg/ml at 10 weeks, 112.6617.9 pg/ml at 11 weeks and
106622.7 pg/ml at 12 weeks (Figure 1B).
sEng serum concentrations remained unchanged throughout
early pregnancy with mean serum concentrations (6SEM) being
2661.4 ng/ml at 6 weeks, 28.961.4 ng/ml at 7 weeks, 26.36
0.8 ng/ml at 8 weeks, 2661.2 ng/ml at 9 weeks, 26.361.2 ng/ml
at 10 weeks, 24.860.6 ng/ml at 11 weeks and 2361.1 ng/ml at
12 weeks (Figure 1C).
Given sFlt1 is capable of antagonizing PlGF, we carried out a
correlation between sFlt1 and PlGF to further assess the potential
relationship between the two throughout the first trimester (data
not shown), however identified no relationship between the two
factors in normal pregnancies when assessing either the raw values
(r
2=0.06) or the MoMs (r
2=0.02).
sFlt1, but not PlGF or sEng is decreased preceding
symptoms of miscarriage
There was a significant decrease (35%, p,0.05) in circulating
sFlt1 (Figure 2A) in serum among the miscarriage cohort from
Figure 1. Analysis of sFlt1 (A), PlGF (B) and sEng (C) in maternal
serum from normal pregnancies (black bars) and pregnancies
that went onto miscarry (white bars) throughout the first
trimester. In normal pregnancies, a non-parametric ANOVA revealed
that sFlt1 and PlGF significantly (p#0.05) increased throughout the first
trimester whilst sEng did not change. No differences were detected
between control and miscarriage groups at each gestation. Data
expressed as mean+ S.E.M.
doi:10.1371/journal.pone.0032509.g001
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delivered a live baby at term (control MoM=1.0 (range 0–3.3), vs
0.65 (range 0–1.94). In contrast, no change was observed in
circulating PlGF or sEng between the two groups (Figure 2B, 2C).
No significant differences were detected between control and
miscarriage groups at each gestational age from 6 to 10 weeks
gestation for sFlt1, PlGF or sEng (Figure 1).
The Receiver Operator Curve (ROC) Area under the curve
(AUC) for sFlt1 was 0.66 (p=0.03). Therefore, despite a
statistically significant difference in sFlt1 between the miscarriage
cohort and controls, sFLt1 has a poor sensitivity and specificity for
predicting miscarriage in asymptomatic women (data not shown).
Discussion
In this study, we show that early pregnancy maternal sFlt-1 but
not PlGF or sEng levels are significantly lower in asymptomatic
women who go on to miscarry compared to women who progress
to a live birth. However, there is significant overlap between cases
and controls, suggesting serum sFlt1 is unlikely to be useful as a
clinical biomarker. Nevertheless, the depression of sFlt1 in
association with miscarriage provides interesting biological
insights.
Although sFlt1 has recently been proposed as a biomarker of
miscarriage [11,12], our study is novel given it was a large
prospective study recruiting an asymptomatic cohort in the mid-
first trimester with confirmation of fetal viability at the time of
sample collection. We believe this is a clinically useful stage of
pregnancy where prediction of miscarriage may be most useful.
Most previous reports investigating the ability of blood biomarkers
to predict miscarriage have been performed among cohorts
already experiencing symptoms of miscarriage (bleeding and
abdominal pain) [11,12,14]. However, development of a clinical
biomarker in this setting is arguably of limited clinical utility given
by this stage, the most appropriate investigation is serial
ultrasounds. Furthermore, the biological information that could
be inferred from such studies are limited by the fact the
pathophysiology of miscarriage is already advanced (bleeding into
subchorionic spaces leading to vaginal bleeding). In contrast we
believe our samples reflect the endocrinology of miscarriage early
in its pathogenesis when the fetus is still viable and the women is
yet to experience symptoms of miscarriage.
sFlt1 and PlGF have often been studied in the maternal serum
for their predictive value in diseases of pregnancy such as
preeclampsia, intrauterine growth restriction and small for
gestational age infants [10,15,16]. In these conditions, sFlt1
increases in association with pathology whilst PlGF decreases.
This is the first study that has documented the week-by-week
changes in serum PlGF, sFlt1 and sEng across the mid first
trimester (6–11 weeks).
Although generally assessed in later pregnancy, a rise in PlGF
throughout pregnancy in the maternal serum of normal
pregnancies is well established [16,17]. One study in early
pregnancy suggested that rises in PlGF are associated with
increased placental perfusion and placental mass [18] which
would account for the high levels we observed at 11 and 12 weeks
compared to 6–10 weeks gestation. Moreover, PlGF is predom-
inantly expressed in the syncytiotrophoblast, which has direct
contact with the maternal circulation [19] thus allowing release of
high levels of PlGF into the maternal circulation as the placental
mass increases. Interestingly it has also been shown that higher
levels of PlGF in early pregnancy are associated with a decreased
risk of disease in later pregnancy, suggesting that low circulating
PlGF may be indicative of defective placentation [15].
Figure 2. Analysis of MoM for serum concentrations of sFlt1
(A), PlGF (B), and sEng (C) between control and miscarriage
cohorts. sFlt1 was signifcantly decreased in the miscarraige cohort
compared to control, whilst no change in PlGF or sEng was detected.
Data is displayed as a box and whisker’s plot with median and 5–95
th
percentiles shown. p#0.05=*.
doi:10.1371/journal.pone.0032509.g002
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in later pregnancy [20], in normal first trimester pregnancies high
levels of sFlt1 are believed to be physiological and a result of
excessive placental production under hypoxic conditions [21].
sFlt1 is an anti-angiogenic factor that antagonizes both VEGF and
PlGF. Free VEGF is undetectable in maternal serum, presumably
due to it being bound by sFlt1, whilst high circulating sFlt1 has
been associated with lower circulating PlGF [16]. While of
uncertain significance, it is intriguing we observed a sudden
increase in serum sFlt1 and PlGF concentrations at 11 and 12
weeks correlates with a period where trophoblast plugs dislodge
and there is sudden perfusion of the intervillous space. This sudden
perfusion is thought to render the placenta less hypoxic than in
earlier pregnancy.
We were able to detect the presence of sEng but observed no
change in levels across 6–12 weeks gestation, a time when there is
increasing placental mass. This raises the possibility that in early
pregnancy serum sEng may be from an extra-placental source
such as the maternal endothelium.
Two studies [11,22] have recently flagged sFlt1 and PlGF as
potential biomarkers of early pregnancy loss using samples
collected from women presenting with symptoms of miscarriage
such as abdominal pain or vaginal bleeding. In agreement with
these, our analysis of MoMs clearly indicated a decline in sFlt1 in
samples from pregnancies that went on to miscarry compared to
those who went on to produce live offspring. This is particularly
interesting as it is suggestive of defective placentation before the
onset of symptoms of miscarriage. Given the delicate balance that
promotes placentation under hypoxic conditions in normal early
pregnancies, including successful angiogenesis and regulation of
pro- and anti- angiogenic factors such as VEGF and sFlt1, our
findings suggest an imbalance of pro and anti-angiogenic factors
may be an early step in the pathophysiological process of
miscarriage which, in turn, may be precipitated by differences in
oxygen tension. However, in contrast to previous studies that have
examined a symptomatic cohort [11,12], our study suggests sFlt1 is
unlikely to be a clinical useful predictor of miscarriage among
asymptomatic women in the first trimester.
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